SCHEDULE 13G/A: Eventide Asset Management Discloses 3.61% Stake in Nektar Therapeutics

Eventide Asset Management, along with Finny Kuruvilla and Robin C. John, has disclosed a beneficial ownership of 3.61% of Nektar Therapeutics' common stock as of December 31, 2024.

Summary

• Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph.D., and Robin C. John have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Nektar Therapeutics.
• The filing reports an aggregate beneficial ownership of 6,650,000 shares of Nektar Therapeutics' common stock.
• This stake represents 3.61% of the total outstanding common stock of Nektar Therapeutics.
• Eventide Asset Management, LLC holds sole voting and dispositive power over these 6,650,000 shares.
• Finny Kuruvilla, M.D., Ph.D., and Robin C. John hold shared voting and dispositive power over the same 6,650,000 shares.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing disclosing beneficial ownership and does not contain information that would significantly alter sentiment, as it's a passive investment disclosure.

Future Outlook

NA

Industry Context

This filing indicates a significant institutional investor's stake in Nektar Therapeutics, a biotechnology company. Such disclosures are routine for institutional investors and provide transparency regarding major shareholdings in the sector.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Eventide Asset Management may provide some level of confidence or indicate continued institutional interest in Nektar Therapeutics.

Key Dates

Keywords

Nektar Therapeutics, Eventide Asset Management, Schedule 13G, beneficial ownership, common stock, institutional investor, biotechnology, pharmaceuticals, NKTR